Mesoblast (ASX:MSB) unveiled new data at the 2026 tandem meetings of the ASTCT and CIBMTR, reinforcing the efficacy of Ryoncil (remestemcel-L) for treating steroid-refractory acute graft-versus-host disease.
The findings highlight a critical clinical insight: earlier intervention with Ryoncil significantly improves patient outcomes across both pediatric and adult populations.
The study analysed data from an Emergency Investigational New Drug program involving 53 patients with severe Grade III/IV disease.
Results demonstrated that Ryoncil achieved consistently high survival rates regardless of age or whether patients were resistant to ruxolitinib.
In the EIND group—where Ryoncil was used as a third-line therapy or later—15% of patients died before completing the full treatment course.
In contrast, only 2% of patients in the Phase 3 MSB-GVHD001 trial, who received the drug as a second-line therapy, faced similar outcomes.
"Treatment initiation as early as possible is essential to give Ryoncil the best chance to save lives," stated Mesoblast CEO Dr. Silviu Itescu.
Based on the favourable survival data in adults, Mesoblast plans to launch a pivotal trial this quarter evaluating Ryoncil as a second-line treatment for adults with SR-aGvHD.
At the time of reporting, Mesoblast's share price was $2.46.